Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L)

Journal of Immunology

Volumn 163, Issue 8, 1999, Pages 4462-4472

  Winter, Hauke ^a,d   Hu, Hong Ming ^a,b   Urba, Walter J ^a,b   Fox, Bernard A ^a,b,c  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 4; PERFORIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; EFFECTOR CELL; FEMALE; GENOTYPE; IMMUNOTHERAPY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD95; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; INJECTIONS, SUBCUTANEOUS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LIGANDS; LYMPHOPROLIFERATIVE DISORDERS; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

EID: 0032853311     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Chang, A. E., A. Yoshizawa, K. Sakai, M. J. Cameron, V. K. Sondak, and S. Shu. 1993, Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 53:1043.
2. Chang, A. E., A. Aruga, M. J. Cameron, V. K. Sondak, D. P. Normolle, B. A. Fox, and S. Shu. 1997. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J. Clin. Oncol. 15:796.
3. Chauvenet, P. H., C. P. McArthur, and R. T. Smith. 1979. Demonstration in vitro of cytotoxic T cells with apparent specificity toward tumor-specific transplantation antigens on chemically induced tumors. J. Immunol 123:2575.
4. Fernandez-Cruz, E., B. Halliburton, and J. D. Feldman. 1979. In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J. Immunol. 123:1772.
5. Kedar, E., M. Schwartzbach, Z. Raanan, and S. Hefetz. 1977. In vitro induction of cell-mediated immunity to murine leukemia cells. II. Cytotoxic activity in vitro and tumor-neutralizing capacity in vivo of anti-leukemia cytotoxic lymphocytes generated in macrocultures. J. Immunol. Methods 16:39.
6. Oehler, J. R., and R. B. Herberman. 1979. Evidence for long-lasting tumor immunity in a syngeneic rat lymphoma model: correlation of in vitro findings with in vivo observations. J. Natl. Cancer Inst. 62:525.
7. Rosenau, W., and H. D. Moon. 1966. Studies on the mechanism of the cytolytic effect of sensitized lymphocytes. J. Immunol. 96:80.
8. Barth, R. J., Jr., S. N. Bock, J. J. Mule, and S. A. Rosenberg. 1990. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J. Immunol. 144:1531.
9. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Y. Shu. 1991. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 134:473.
10. Yoshizawa, H., A. E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:729.
11. Shu, S. Y., T. Chou, and S. A. Rosenberg. 1987. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 139:295.
12. Shu, S., R. A. Krinock, T. Matsumura, J. J. Sussman, B. A. Fox, A. E. Chang, and D. S. Terman. 1994. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J. Immunol. 152:1277.
13. Matsumura, T., R. A. Krinock, A. E. Chang, and S. Shu. 1993. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor. Cancer Res. 53:4315.
14. Kagi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528.
15. Kagi, D., P. Seiler, J. Pavlovic, B. Ledermann, K. Burki, R. M. Zinkernagel, and H. Hengartner. 1995. The roles of perform- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur. J. Immunol. 25: 3256.
16. Henkart, P. 1999. Cytotoxic T Lymphocytes. Raven Press, New York.
17. Podack, E. R., H. Hengartner, and M. G. Lichtenheld. 1991. A central role of perforin in cytolysis? Annu. Rev. Immunol. 9:129.
18. Podack, E. R., and A. Kupfer. 1991. T-cell effector functions: mechanisms for delivery of cytotoxicity and help. Annu. Rev. Cell Biol. 7:479.
19. Anel, A., M. Buferne, C. Boyer, A. M. Schmitt-Verhulst, and P. Golstein. 1994. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur. J. Immunol. 24:2469.
20. Li, J. H., D. Rosen, D. Ronen, C. K. Behrens, P. H. Krammer, W. R. Clark, and G. Berke. 1998. The regulation of CD95 ligand expression and function in CTL. J. Immunol. 161:3943.
21. Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305.
22. Blanckaert, V. D., M. E. Schelling, C. A. Elstad, and G. G. Meadows. 1993. Differential growth factor production, secretion, and response by high and low metastatic variants of B16BL6 melanoma. Cancer Res. 53:4075.
23. Hu, H. M., W. J. Urba, and B. A. Fox. 1998. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 161:3033.
24. Arca, M. J., J. C. Krauss, A. Aruga, M. J. Cameron, S. Shu, and A. E. Chang. 1996. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther. 3:39.
25. Thompson, T. C., L. D. Truong, T. L. Timme, D. Kadmon, B. K. McCune, K. C. Flanders, P. T. Scardino, and S. H. Park. 1993. Transgenic models for the study of prostate cancer. Cancer 71:1165.
26. Shu, S. Y., and S. A. Rosenberg. 1985. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 45:1657.
27. Fox, B. A., and S. A. Rosenberg. 1989. Heterogeneous lymphokine-activated killer cell precursor populations: development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires. Cancer Immunol. Immunother, 29:155.
28. Sayers, T. J., A. D. Brooks, J. K. Lee, R. G. Fenton, K. L. Komschlies, J. M. Wigginton, R. Winkler-Pickett, and R. H. Wiltrout. 1998. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells [In Process Citation]. J. Immunol. 161:3957.
29. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161:897.
30. Aruga, A., E. Aruga, K. Tanigawa, D. K. Bishop, V. K. Sondak, and A. E. Chang. 1997. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J. Immunol. 159:664.
31. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
32. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:3359.
33. Dailey, M. O., E. Pillemer, and I. L. Weissman. 1982. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc. Natl. Acad. Sci. USA 79:5384.
34. Rosenstein, M., and S. A. Rosenberg. 1984. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies. J. Natl. Cancer Inst. 72:1161.
35. Yamasaki, T., H. Handa, J. Yamashita, Y. Watanabe, Y. Namba, and M. Hanaoka. 1984. Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas. Cancer Res. 44:1776.
36. + cells: cytolytic T cells can mediate eradication of disseminated leukemia. J. Immunol. 136:1917.
37. Spiess, P. J., J. C. Yang, and S. A. Rosenberg. 1987. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst. 79:1067.
38. Yoshizawa, H., A. E. Chang, and S. Y. Shu. 1992. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res. 52:1129.
39. Kagi, D., B. Ledermann, K. Burki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31.
40. van den Broek, M. E., D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W. K. Lutz, C. J. Melief, R. M. Zinkernagel, and H. Hengartner. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184:1781.
41. + T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur. J. Immunol. 24:3068.
42. Kagi, D., B. Ledermann, K. Burki, R. M. Zinkemagel, and H. Hengartner. 1996. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 14:207.
43. Kagi, D., and H. Hengartner. 1996. Different roles for cytotoxic T cells in the control of infections with cytopathic versus noncytopathic viruses. Curr. Opin. Immunol. 8:472.
44. Cooper, A. M., C. D'Souza, A. A. Frank, and I. M. Orme. 1997. The course of Mycobacterium tuberculosis infection in the lungs of mice lacking expression of either perforin- or granzyme-mediated cytolytic mechanisms. Infect. Immun. 65: 1317.
45. Laochumroonvorapong, P., J. Wang, C. C. Liu, W. Ye, A. L. Moreira, K. B. Elkon, V. H. Freedman, and G. Kaplan. 1997. Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice. Infect. Immun. 65:127.
46. Nakamoto, Y., L. G. Guidotti, V. Pasquetto, R. D. Schreiber, and F. V. Chisari. 1997. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. J. Immunol. 158:5692.
47. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
48. Ramsdell, F., M. S. Seaman, R. E. Miller, K. S. Picha, M. K. Kennedy, and D. H. Lynch. 1994. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int. Immunol. 6:1545.
49. Singer, G. G., and A. K. Abbas. 1994. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1:365.
50. + T-cell mechanisms in the control of respiratory virus infections. Immunol. Rev. 159:105.
51. Carter, L. L., and R. W. Dutton. 1995. Relative perforin- and Fas-mediated lysis in T1 and T2 CD8 effector populations. J. Immunol. 155:1028.
52. Nagata, S. 1997. Apoptosis by death factor. Cell 88:355.
53. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J. L. Bodmer, M. Schroter, K. Burns, C. Mattmann, D. Rimoldi, L. E. French, and J. Tschopp. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388:190.
54. Thomas, W. D., and P. Hersey. 1998. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:2195.
55. + tumor-draining lymph node cells involved in mediating tumor regression. J. Leukocyte Biol. 61:507.
56. Nagoshi, M., P. S. Goedegebuure, U. L. Burger, N. Sadanaga, M. P. Chang, and T. J. Eberlein. 1998. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyle/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes. J. Immunol. 160:334.
57. Weber, J. S., G. Jay, K. Tanaka, and S. A. Rosenberg. 1987. Immunotherapy of a murine tumor with interleukin 2: increased sensitivity after MHC class I gene transfection. J. Exp. Med. 166:1716.
58. Meltzer, M. S. 1981. Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J. Immunol. 127:179.
59. Pace, J. L., S. W. Russell, B. A. Torres, H. M. Johnson, and P. W. Gray. 1983. Recombinant mouse γ interferon induces the priming step in macrophage activation for tumor cell killing. J. Immunol. 130:2011.
60. Boraschi, D., D. Soldateschi, and A. Tagliabue. 1982. Macrophage activation by interferon: dissociation between tumoricidal capacity and suppressive activity. Eur. J. Immunol. 12:320.
61. Mantovani, A., W. J. Ming, C. Balotta, B. Abdeljalil, and B. Bottazzi. 1986. Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim. Biophys. Acta 865:59.
62. Mule, J. J., M. Rosenstein, S. Shu, and S. A. Rosenberg. 1985. Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). Cancer Res. 45:526.
63. Fidler, I. J. 1994. Therapy of cancer metastasis by systemic activation of macrophages. Adv. Pharmacol. 30:271.
64. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol. 155:2240.
65. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815.
66. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209.
67. Bogdan, C., Y. Vodovotz, and C. Nathan. 1991. Macrophage deactivation by interleukin 10. J. Exp. Med. 174:1549.